Thoratec CFO resigns
This article was originally published in Clinica
David Smith, vice-president and chief financial officer of mechanical heart developer Thoratec, has resigned to "pursue other business opportunities". Mr Smith will stay on until 1 July to assist in the transition to a new CFO. Roxanne Oulman, currently vice-president of finance, will replace him on an interim basis until a permanent successor is named. She joined the Pleasanton, California-based company in 2004. Thoratec has also reiterated its previously issued financial guidance for 2011, predicting full-year revenues of $410-425m and GAAP net income of $1.02-1.12 per diluted share. However, it has recently been hit by concerns over its lead products, the HeartMate I and II artificial heart devices: in April, a study reported that 15% of patients using the products suffered a stroke, a higher risk than previously thought (www.clinica.co.uk, 19 April 2011).
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.